Wenemea is the developer of chemotherapy-induced peripheral neuropathy designed for cancer treatment through neurological screening.
Wenemea has raised $1.1M in total funding. The most recent round was Grant. The last funding was announced in January 2026.
Wenemea's investors include Eurostars.
Wenemea is headquartered in Aarhus, Denmark.
Wenemea is the developer of chemotherapy-induced peripheral neuropathy designed for cancer treatment through neurological screening.
Wenemea is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Wenemea — Funding & Investors." VCBacked, January 21, 2026, https://www.vcbacked.co/company/wenemea. Accessed August 14, 2026.
VCBacked. (2026). Wenemea — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/wenemea
{{cite web |title=Wenemea — Funding & Investors |url=https://www.vcbacked.co/company/wenemea |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated